Navigation Links
Negative iron balance predicts acute heart failure survival
Date:5/17/2014

s expressed on all cells and enables iron to enter the cell. When there is not enough iron in the cell, the receptor is overexpressed and shed into the circulation. Concomitance of low hepcidin and high soluble transferrin receptor reflects the most severe form of iron deficiency (lack of iron in the body accompanied by iron need), which the investigators called negative iron balance (NIB).

This prospective, observational study included 165 patients hospitalised for acute heart failure. The researchers assessed the prevalence of NIB and its impact on 12 month mortality.

NIB was found in 37% of patients. Just 29% had only high soluble transferrin receptor, while 9% had only low hepcidin and 25% had none of these abnormalities. Twelve month mortality was 20% for the whole group. Patients with NIB had the highest 12 month mortality (41%) compared to those with only high soluble transferrin receptor (15%), only low hepcidin (7%) and none of these abnormalities (0%) (p<0.001). During the hospital stay 3 patients died and all had NIB.

Professor Jankowska said: "Our study shows that deranged iron status is common in acute heart failure. Mortality in the patients with NIB was high during the 12 month follow up, whereas all of the patients with no iron abnormalities survived to one year."

NIB led to poorer survival in acute heart failure patients regardless of whether they were anaemic or not.

The researchers also measured the standard parameters of iron status, serum ferritin and TSAT, and found that they were less able to predict 12 month mortality than NIB. Levels of serum ferritin and TSAT were only weakly correlated with hepcidin and soluble transferrin receptor.

Professor Ponikowski said: "Levels of hepcidin and soluble transferrin receptor are more clinically relevant in patients with acute heart failure than traditional measures of iron status. We propose a new pathophysiological definition of iron deficiency whi
'/>"/>

Contact: ESC Press Office
press@escardio.org
33-622-834-576
European Society of Cardiology
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. New way to predict response to chemo in triple-negative breast cancer
2. Triple negative breast cancer, ethnicity, and socioeconomic status
3. Psilocybin inhibits the processing of negative emotions in the brain
4. Gene implicated in progression and relapse of deadly breast cancer finding points to potential Achilles heel in triple negative breast cancer
5. Increased risk of relapse omitting RT in early PET scan negative Hodgkin lymphoma
6. Negative effects of joining a gang last long after gang membership ends
7. HPV-positive SCCOP patients recurrence differs from HPV-negative patients
8. Negative BRCA testing may not always imply lowered breast cancer risk
9. Urinary Tract Infection Market (UTI): Gram-Negative Bacterial 2022 Epidemiology Forecasts in New Research Report at RnRMarketResearch.com
10. Study ties bone marrow transplant to negative sexual side effects
11. Diet Doc Hormone Diets & Weight Loss Plans Announce Advanced Hormone Diet Treatments That Eliminate Unwanted Body Fat Without Negative Drug Effects
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Aeroflow Healthcare, an industry leader and ... the opening of its new office to be located ... Business Parkway, Suite D, Greer, SC 29651. This new ... a more convenient location in the Greenville area. , ... the physicians, hospitals and patients we serve, to ensure ...
(Date:9/2/2014)... “Harmonicas have been formally used in ... help people with COPD or asthma. At this ... says Dana Keller, PhD, co-inventor of the Pulmonica. ... much the same – improved health with the ... , The three approaches to harmonicas in healthcare ...
(Date:9/2/2014)... During the fall season, before the ... winter months to prevent costly damage later on. Pasquali ... company, suggests these fall preventative home maintenance tips. , ... throughout fall to prevent build up of leaves and ... problems, pest infestations, wet basements, foundation damage and many ...
(Date:9/1/2014)... BambooIndustry.com is one of the most ... famous for its high quality and elegant floors, plywoods, ... its new range of solid bamboo floors ... company has confidence in the new collection. BambooIndustry.com is ... of elegant bamboo items and great customer services. Also, ...
(Date:9/1/2014)... Securityhunter has experienced rapid growth ... search for a new, larger headquarters. The newly ... the space of our office to 10,000 square feet. ... from glass topped cubicles with doors, to beautiful large conference ... warehouse," says Michael S. Rogers, CEO of Securityhunter. “Our ...
Breaking Medicine News(10 mins):Health News:Aeroflow Healthcare Opens Office In Greer, SC To Service Greenville & Spartanburg Patients 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 2Health News:Harmonica Techs, Inventor of the Pulmonica Pulmonary Harmonica, Outlines New Uses for Harmonicas in Healthcare 3Health News:Northern Virginia Real Estate Company Pasquali Realty Group Suggests These Maintenance Tips for Homeowners This Fall 2Health News:BambooIndustry.com: Solid Bamboo Floors Provided At Discounted Rates 2Health News:Securityhunter, Inc. Announces the Relocation of Its Corporate Headquarters in Baltimore 2
... RICHMOND, Va., Oct. 28 A leading authority on the ... a looming "caregiver crunch" impacting the ability of Americans to ... their loved ones. , On November 12, Dr. Dychtwald will ... coming "caregiver crunch" and the importance of long term care ...
... BLOOMINGTON, Minn., Oct. 28 The Child Neurology Foundation ... Spasms Awareness Week (October 11-17) that will go towards ... of epilepsy. , "Due to its rare nature, ... as it should be," said Lawrence Brown, M.D., Associate ...
... Biomedical Research Centre (BRC) for Mental Health at South ... of Psychiatry (IoP) , King,s College London (KCL) has ... support the development of the BRC,s Case Register Interactive ... research tool developed by the BRC,s cross-cutting Analytical Methodologies ...
... ... Administration (FDA) approval of its biologics license application (BLA) for the first 15 monoclonal antibodies ... entered into an exclusive agreement with the MED Alliance Group, Inc. (MAGI) to serve as ... ...
... Health & Hospital System is responding to the ... expanding its language access program to include approximately ... other locations throughout Parkland Memorial Hospital. The unique, ... leading interpretation and translation provider, are used to ...
... Morphotek®, Inc., a subsidiary of Eisai Inc., announced today ... Centocor Ortho Biotech Inc. for development and commercialization of ... many solid tumors. , Under the terms ... worldwide license for the development, manufacture and sale of ...
Cached Medicine News:Health News:Dr. Ken Dychtwald to Discuss Looming 'Caregiver Crunch' and the Importance of Proactive Long Term Care Planning 2Health News:Child Neurology Foundation Announces $30,000 Grant for Research Into Cause and Treatment of Infantile Spasms 2Health News:Child Neurology Foundation Announces $30,000 Grant for Research Into Cause and Treatment of Infantile Spasms 3Health News:Quotient Biodiagnostics Signs MED Alliance Group, Inc. as Exclusive Distributor in Midwest for Line of Transfusion Diagnostics 2Health News:Quotient Biodiagnostics Signs MED Alliance Group, Inc. as Exclusive Distributor in Midwest for Line of Transfusion Diagnostics 3Health News:Parkland Health & Hospital System Expands Language Access with Language Line(R) Phones in Every Patient Room 2Health News:Parkland Health & Hospital System Expands Language Access with Language Line(R) Phones in Every Patient Room 3Health News:Morphotek(R), Inc. Announces a Licensing Deal With Centocor Ortho Biotech Inc. for Exclusive Development and Commercialization Rights for a Therapeutic Monoclonal Antibody 2
(Date:9/1/2014)... , Sept. 1, 2014 ... report is available in its catalogue: ... 2024 http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... a new class of therapeutic agents, gaining increasing ... Generally addressed as the marriage of an antibody ...
(Date:8/30/2014)... , Aug. 30, 2014  Boston Scientific ... NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) clinical ... trial investigating vagus nerve stimulation (VNS) for the ... Ph.D., Professor of Therapeutics and Cardiology and Director ... National de la Sante et de la Recherche ...
(Date:8/29/2014)... N.C. , Aug. 29, 2014 The ... (KOLs) can be the difference between a product,s success ... effectively map and stratify KOL targets – and then ... the type of strong relationships upon which successful KOL ... savvy pharma companies have identified internal inconsistencies in their ...
Breaking Medicine Technology:Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 2Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 3Boston Scientific Announces Primary Endpoint Results of NECTAR-HF Clinical Trial 4Implementing a Strategic Thought Leader Management & Engagement System 2
... Dec. 21, 2010 Bellicum Pharmaceuticals, Inc. today announced ... will be used to prepare for Phase II trials ... resistant prostate cancer (mCRPC), and CaspaCIDe™, a cell therapy ... cell therapy (HSCT) setting. The new funding ...
... Dec. 21, 2010 The American Heart Journal ... Amorcyte, Inc.,s lead product candidate, AMR-001 for the treatment ...  Data demonstrated a significant relationship between cell dose and ... to prospectively define a dose of a purified and ...
Cached Medicine Technology:Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding 2Amorcyte Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients 2Amorcyte Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: